Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Carcinoma, Hepatocellular 23Esophageal Squamous Cell Carcinoma 22Triple Negative Breast Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Advanced Solid Tumor 17Melanoma 15Stomach Neoplasms 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Head and Neck Neoplasms 8Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Nasopharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

Gemcitabine 6Cisplatin 6Capecitabine 6Liver Transplantation 4Fluorouracil 4Specimen Handling 3Radiosurgery 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3toripalimab 2dehydroftorafur 2Self Expandable Metallic Stents 2Platinum 2Leucovorin 2Biopsy 23-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 21,2-diaminocyclohexaneplatinum II citrate 2trisacryl gelatin microspheres 1tremelimumab 1trametinib 1tislelizumab 1temoporfin 1sacituzumab govitecan 1ricolinostat 1pembrolizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1durvalumab 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Klatskin Tumor × toripalimab × Clear all
NCT06717464 2024-12-05

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Active not recruiting
110 enrolled
Gastrointestinal

Gallbladder Neoplasms, Klatskin Tumor

NCT04211168 2023-03-29

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Peking Union Medical College Hospital

Phase 2 Unknown
44 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡